Búsqueda de un ensayo clínico
Otra(s) opcion(es) de búsqueda
18 Resultado(s)
Ensayo clínico en reclutamiento
= 
; Ensayos clínico en curso
= 
; Financiado por un miembro del IRDiRC = 
; Miembro de una ERN = 
Ensayo(s) clínico(s) nacional(es)
ALEMANIA
Baden-Württemberg
ULM
Cadenza Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion -DE-
DRK Baden-Württemberg/ Hessen
Institut für Klinische Transfusionsmedizin und Immungenetik Ulm
ALEMANIA
Baden-Württemberg
ULM
Cardinal study: A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion -DE-
DRK Baden-Württemberg/ Hessen
Institut für Klinische Transfusionsmedizin und Immungenetik Ulm
ALEMANIA
Nordrhein-Westfalen
ESSEN
Cardinal study: A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion -DE-
Universitätsklinikum Essen
ALEMANIA
Nordrhein-Westfalen
ESSEN
DECADE Trial: Therapy for Chronic Cold Agglutinin Disease: A prospective, non-randomized multicentre phase II study demonstrating the efficacy of terminal complement inhibition in patients with Cold Agglutinin Disease using Eculizumab
Westdeutsches Tumorzentrum Essen (WTZ)
Klinik für Hämatologie
ALEMANIA
Nordrhein-Westfalen
ESSEN
Cadenza Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion -DE-
Westdeutsches Tumorzentrum Essen (WTZ)
Klinik für Hämatologie
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
Cardinal Study: A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion - AT
Institution: Information not provided - AT
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
A Phase 2, Single-Center, Open-Label, Repeat-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Intravenous ANX005 in Participants with Primary Cold Agglutinin Disease
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study
Allgemeines Krankenhaus der Stadt Wien
Universitätsklinik für klinische Pharmakologie
AUSTRIA
WIEN
WIEN
Cadenza Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion - AT
Allgemeines Krankenhaus der Stadt Wien
Universitätsklinik für klinische Pharmakologie
BELGICA
VLAAMS BRABANT
LEUVEN
Cadenza Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion - BE
UZ Leuven - Campus Gasthuisberg
Department of Hematology
BELGICA
VLAAMS BRABANT
LEUVEN
Cardinal Study: A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion - AT
UZ Leuven - Campus Gasthuisberg
Department of Hematology
ESPAÑA
Madrid
ADDRESS: NOT PROVIDED - ES
Estudio basket de fase 2, multicéntrico y abierto para evaluar la eficacia, la seguridad y la farmacocinética de iptacopán (LNP023) en participantes con trastornos hematológicos autoinmunes benignos
Institution: Information not provided - ES
REINO UNIDO (EL)
West Yorkshire
LEEDS
Cadenza Study: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion-GB
St James's University Hospital
The Leeds Teaching Hospitals NHS Trust HQ
REINO UNIDO (EL)
West Yorkshire
LEEDS
Cardinal study: A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion-GB
St James's University Hospital
The Leeds Teaching Hospitals NHS Trust HQ
AUSTRIA
WIEN
ADDRESS: NOT PROVIDED - AT
Very low doses of Rituximab for off-label treatment - a Pilot Trial (Phase 2)
Institution: Information not provided - AT
AUSTRIA
WIEN
WIEN
A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia - AT
Allgemeines Krankenhaus der Stadt Wien
Klinische Abteilung für Hämatologie und Hämostaseologie
ESTADOS UNIDOS
Delaware
WILMINGTON
A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia-FR
Incyte Corporation
Ensayo(s) clínico(s) multinacional(es)
ESTADOS UNIDOS
Delaware
WILMINGTON